Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02570542 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)
Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

PROCEDURE: leukapheresis
DRUG: Plerixafor
DRUG: carmustine, etoposide, cytarabine, melphalan
PROCEDURE: Autologous Stem Cell Transplantation

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]